The lack of dopamine disrupts communication between neurons that control movement. By the time motor symptoms appear and PD is diagnosed, a substantial proportion of dopaminergic neurons have already been lost.
PD is known as a “synucleinopathy,” which means that the disease is characterized by the accumulation of pathological alpha-synuclein. It misfolds and clumps into aggregates that accumulate in the brain and are thought to contribute to cell death and disease onset.
Levodopa, introduced more than 60 years ago, was a miracle drug in helping to control Parkinson’s symptoms. It is highly effective early on, but its benefit declines as the disease progresses, and long-term use can induce dyskinesias in many patients. Levodopa treats symptoms only, does not stop protein misfolding, and no approved therapy slows or halts the underlying neurodegeneration.
At Brain Chemistry Labs, we have identified a naturally occurring molecule that, in preclinical studies, significantly reduces misfolding and aggregation of alpha-synuclein.
Brain Chemistry Labs is planning a Phase II clinical trial in patients with PD to test the efficacy of this naturally occurring molecule. Subject to FDA clearance, the trial is expected to begin in 2027.
Simultaneously, Brain Chemistry Labs is also developing a miRNA blood test to identify PD in patients and assist clinicians in making an earlier diagnosis. This test will follow the same CLIA/CAP validation as the ALS Test.
Phase II
Planned, to test a naturally occurring molecule against alpha-synuclein misfolding. Subject to FDA clearance, expected to begin in 2027.
- TargetAlpha-synuclein
- PreclinicalReduced misfolding
- Trial start2027, subject to FDA
- Blood testmiRNA, in development

